Fang XQ, Gan T, Wang LM. Clinical effect of spleen aminopeptide on improving liver function damage and immune function in children with infant hepatitis syndrome. World J Gastrointest Surg 2024; 16(6): 1742-1748 [PMID: 38983347 DOI: 10.4240/wjgs.v16.i6.1742]
Corresponding Author of This Article
Lie-Min Wang, Bachelor, Nurse-in-Charge, Department of Neonatal, Central Hospital of Enshi, No. 88 Jinlong Avenue, Enshi 445000, Hubei Province, China. lieminwang@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Clinical Trials Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Jun 27, 2024; 16(6): 1742-1748 Published online Jun 27, 2024. doi: 10.4240/wjgs.v16.i6.1742
Clinical effect of spleen aminopeptide on improving liver function damage and immune function in children with infant hepatitis syndrome
Xiao-Qing Fang, Tian Gan, Lie-Min Wang
Xiao-Qing Fang, Department of Pediatrics, General Hospital of Central Theater Command of PLA, Wuhan 430061, Hubei Province, China
Tian Gan, Department of Pharmacy, The First People’s Hospital of Jiangxia District, Wuhan 430200, Hubei Province, China
Lie-Min Wang, Department of Neonatal, Central Hospital of Enshi, Enshi 445000, Hubei Province, China
Co-first authors: Xiao-Qing Fang and Tian Gan.
Author contributions: Fang XQ and Gan T designed the research; Fang XQ, Gan T and Wang LM contributed new reagents/analytic tools; Fang XQ, Gan T and Wang LM analyzed the data; Fang XQ and Gan T wrote the paper; All authors were involved in the critical review of the results and have contributed to, read, and approved the final manuscript.
Institutional review board statement: This study protocol was approved by The First People's Hospital of Jiangxia District.
Informed consent statement: All the families have voluntarily participated in the study and have signed informed consent forms. We explained the purpose, process, risks and benefits of the study to all individuals involved in the study orally or in writing, and obtained their informed consent. Participants have the right to know that their participation is voluntary and can withdraw from the study at any time.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Data generated from this investigation are available upon reasonable quest from the corresponding author.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lie-Min Wang, Bachelor, Nurse-in-Charge, Department of Neonatal, Central Hospital of Enshi, No. 88 Jinlong Avenue, Enshi 445000, Hubei Province, China. lieminwang@163.com
Received: April 3, 2024 Revised: May 13, 2024 Accepted: May 24, 2024 Published online: June 27, 2024 Processing time: 87 Days and 16.9 Hours
Abstract
BACKGROUND
Infant hepatitis syndrome (IHS) is a clinical syndrome in infants less than one year of age with generalized skin jaundice, abnormal liver function, and hepatomegaly due to various etiologies such as infection.
AIM
To investigate the effect of IHS patients, after treatment with arsphenamine-based peptides, on patients' liver function damage and immune function.
METHODS
Of 110 patients with IHS treated in our hospital from January 2019 to January 2021 were grouped according to the randomized residual grouping method, with 5 cases in each group shed due to transfer, etc. Ultimately, 50 cases remained in each group. The control group was treated with reduced glutathione, and the treatment group was treated with sesquiterpene peptide based on the control group. Observe and compare the differences in indicators after treatment.
RESULTS
The comparison of serum total bilirubin, direct bilirubin, and serum alanine transferase after treatment was significantly different and lower in the treatment group than in the control group (P < 0.05). The comparison of CD4+, CD3+, CD4+/CD8+ after treatment was significantly different and higher in the treatment group than in the control group, and the comparison was statistically significant (P < 0.05). The complication of the two groups showed that the rash, cough and sputum, elevated platelets, and gastrointestinal reactions in the treatment group were significantly lower than those in the control group, and the differences were statistically significant by test (P < 0.05).
CONCLUSION
The comparative study of IHS treated with arsphenamine combined with reduced glutathione is more effective.
Core Tip: In this study, infant hepatitis syndrome (IHS) is a clinical syndrome in infants less than one year of age with generalized skin jaundice, abnormal liver function, and hepatomegaly due to various etiologies such as infection. The comparative study of IHS was better treated with splenamine combined with reduced glutathione, which effectively improved patients' liver function and immune level, reduced adverse reactions, and provided some reference value for clinical treatment of IHS.
